‘Miracle Mineral Solution’ Is No Miracle Cure, FDA Warns
When mixed, the solution develops into a dangerous bleach.
FDA
FDA Warns CBD Product Maker About False Claims
Agency says unproven claims about CBD products could lead consumers to delay medical care.
The FDA Seeks Your Feedback on New Measure for Fixed-Quantity Blister Packaging for Opioids
The US Food and Drug Administration is seeking feedback from healthcare professionals on its proposal to offer fixed-quantity blister packaging for a select number of opioid medications.
FDA Approves Venetoclax for Chronic Lymphocytic Leukemia
In randomized trial, drug demonstrated statistically significant improvement in progression-free survival.
Two-Thirds of Sunscreens Fail Safety Tests
More than 60% of products do not provide adequate sun protection, contain potentially harmful chemicals.
FDA Approves Ruzurgi for Children With Rare Autoimmune Disorder
Ruzurgi previously approved for treatment in adults with Lambert-Eaton myasthenic syndrome.
FDA Passes on Barhemsys NDA Again Due to Facility Issues
The FDA has issued a second complete response letter to Acacia Pharma regarding the New Drug Application for Barhemsys (amisulpride injection).
FDA: Breast Implants Linked to Cancer Can Still Be Sold in US
Agency considering new patient warnings and checklists for the implants.
FDA Puts Tough Warning Label on Ambien, Lunesta, Other Sleep Aids
Move spurred by 66 cases of ‘complex sleep behaviors’ after taking the insomnia medications.
FDA Launches “Remove the Risk” Campaign for Safe Disposal of Unused Opioids
The U.S. Food and Drug Administration is launching on April 25, 2019, its “Remove the Risk” campaign, aimed at promoting the safe disposal of unused opioids.
Next post in Pain Information Center
